Dementia is a common neuropsychiatric syndrome that is usually chronic or progressive and causes deterioration of various mental functions, including cognitive, emotional, and mental.
INTRODUCTION
mentia or included PWD in the later stages, [16] [17] [18] [24] [25] [26] [27] [28] [29] [30] and the efficacy and/or mechanisms of NPIVs may differ in later stages of dementia compared to those in the earlier stages. 7, 8 Although three systematic reviews on the efficacy of NPIVs in people with moderate to severe dementia (PWMSD) have been conducted, the effect sizes of the NPIVs were not reported because the reviews were not meta-analyses. Furthermore, the times of publication or intervention settings of the studies included in the meta-analyses were limited. 16, 17, 23, 31, 32 The principal strength of a systematic review is the capacity to identify salient and critical studies through the unmanageable numbers of existing medical literature using critical exploration, valuation, and synthesis. 33 Second, the results of a systematic review could satisfy the need of decision makers for evidence-based integrated results. 33 Conducting a systematic review, it is possible to refine the literature on the efficacy of NPIV in PWMSD by conducting qualitative synthesis and quantitative analysis, and also provide decision makers with reliable and pertinent evidence.
METHODS Purpose
This systematic review, which will include a meta-analysis, aims to identify and evaluate the efficacy of NPIVs on the ADL and BPSD of PWMSD. Thus, the proposed systematic review will attempt to answer the following research questions: 1) Which NPIVs improve the ADL and BPSD of PWMSD? 2) What are the effects of NPIVs on the ADL and BPSD of PWMSD?
Methodology
This systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 34 and Cochrane Handbook for Systematic Reviews of Interventions. 35 This systematic review protocol is registered with the PROSPERO (CRD42017058020).
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Eligibility criteria
Populations
The systematic review will include studies involving people diagnosed with any type of dementia according to the criteria in the Diagnostic and 
Interventions
This systematic review will include studies involving any type of NPIV that were conducted in community settings or institutional settings. NPIVs can be categorized in four broad groups following the practice guideline, 8 and we will include several treatments such as cognitive therapy, art therapy, aromatherapy, massage, animal assisted therapy, exercise, or horticultural therapy.
Outcomes
This systematic review will employ ADL and BPSD as the primary outcomes and cognitive function and QoL as the secondary outcomes.
Study design
This systematic review will include randomized control trials (RCTs), quasi RCTs, non RCTs, cross-sectional studies, interrupted time series, and before-after studies that used the Study Design Algorithm for Medical Literature on Intervention.
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Information sources
This systematic review will search the following databases and reference lists of the included studies: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE ® , EM-BASE ® , CINAHL, PsycINFO, KoreaMED, KMbase, and KISS. This systematic review will not limit the geography or time of the study, but only publications written in English or Korean will be included.
Search strategy
One reviewer (R Na) will search the information sources. The search strategy will include the study population and intervention terms suggested by Medical Subject Headings (MeSH ® ) and Emtree ® . The search terms will be adapted for use in other bibliographic databases with database-specific filters when available. Some syntax, including truncation, or Boolean operators, will be amended to the specific databases. A draft EMBASE search strategy is shown in Table 1 . This EM-BASE search strategy will be adapted to the syntax and subject headings of the other databases. 
Selection process
Two reviewers (R Na and YJ Kim) will independently select studies in the three phases listed below. If any discrepancies occur between the two reviewers, two additional reviewers (KW Kim and K Kim) will amend the decision. This systematic review will create a PRISMA flow diagram of the included and excluded studies.
1) Initial screening: potential papers will be identified for abstract retrieval, and any obviously irrelevant studies will be eliminated by screening their titles.
2) Secondary screening: potential papers will be identified for full text retrieval by screening their abstracts.
3) Tertiary screening: papers that should be included in the current systematic review will be identified by reading the full text, and the reasons for exclusion will be documented.
Data collection process
Two reviewers (R Na and YJ Kim) will collect the data. Eligible data will be independently extracted with a standardized form. Any discrepancies will be resolved by deliberation between R Na and YJ Kim or, if needed, with two other reviewers (KW Kim and K Kim).
Data items
Two reviewers (R Na and YJ Kim) will extract the data from the publications with a standardized data extraction form. The extracted data will be summarized as shown in Table 2 .
Outcomes and prioritization
Primary outcomes
The primary outcomes of this systematic review will be ADL and BPSD of PWMSD. ADL, which will include Basic and Instrumental ADL, 38 will be measured with standardized assessment scales, including the AD Cooperative Study' s ADL scale, Barthel Index, Disability Assessment for Dementia, DScale of Change, Katz Index, modified instrumental ADL scale, modified Physical Self-Maintenance Scale, Functional Independence Measure, and Nurse Informant Index of Activities of Daily Living. 12, [38] [39] [40] [41] [42] [43] The other primary outcome, BPSD, represents a heterogeneous group of noncognitive symptoms and behaviors. 44 BPSD includes agitation, aggression, aberrant motor behavior, anxiety, elation, irritability, depression, dysphoria, apathy, dis- 
Secondary outcomes
The secondary outcomes will include the cognitive function The evaluations of the QoL variables in PWD will require standardized and validated QoL scales, such as the Quality of Life scale in AD, AD Related Quality of Life, Dementia-Quality of Life, EuroQoL-Five Dimensions Questionnaire, and Blau's QoL Scale.
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Risk of bias in individual studies
Two reviewers (R Na and YJ Kim) will independently assess the risk of bias (RoB) in each study. All reviewers will discuss the quality of a study if the two reviewers disagree. The RoB of RCTs will be assessed with the RoB scale, 60 while the RoB of nonRCTs will be assessed with the RoB Assessment Tool for Nonrandomized Studies (RoBANS). 61 Each included study will be classified as low risk, high risk, or unclear according to the RoB and/or RoBANS.
Data synthesis
Two reviewers (YJ Kim and R Na) will conduct a meta-analysis of the outcomes with Review Manager if a sufficient number of studies are included. They will employ risk and odds ratios with 95% confidence intervals (CIs) for dichotomous outcomes and weighted mean differences (with 95% CIs) or standardized mean differences (with 95% CIs) for continuous outcomes. For missing data, we will attempt to contact the authors of the study to obtain the relevant information. Intention-to-treat data, if available, will be preferred.
This systematic review will consider the various characteristics of the participants and the study designs when evaluating the heterogeneity of the studies. Heterogeneity will be statistically tested with the chi-squared and I-squared tests. 35 To address heterogeneity, a meta-analysis will be conducted by considering the following: re-examining the data for accuracy, canceling the meta-analysis, exploring the heterogeneity, ignoring the heterogeneity, performing a random-effects metaanalysis, changing the effect measure, and/or excluding studies. 35 This systematic review will conduct subgroup analyses of the participants (e.g., dementia subtype, dementia severity, or participant characteristics), interventions (types, providers, or settings), study designs, and follow-up periods if sufficient data are available.
Meta-biases
This systematic review will assess publication bias with funnel plots of potential reporting bias if the number of studies in the meta-analysis is over 10.
Confidence in the cumulative estimates
This systematic review will assess the quality of the evidence for all outcomes with the Grading of Recommendations Assessment, Development and Evaluation (GRADE). 62 All reviewers will determine the quality of the evidence according to the GRADE guidelines.
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CONCLUSION
This systematic review will examine the clinical efficacy of NPIVs on the ADL, BPSD, cognitive function, and QoL of PWMSD. Although the efficacy of NPIVs on PWD may differ according to the severity of dementia, recent reviews on NPIVs for PWD have not separately evaluated NPIVs efficacy on PWMSD or conducted relevant meta-analyses. To maximize the power of systematic reviews, restriction of publication language is not recommended. However, this systematic review will include studies written in English or Korean only for practical reasons, which will be a limitation of this study.
Nonetheless, this systematic review will provide clinicians and policy makers with reliable evidence for developing and implementing NPIVs for PWMSD.
